Janney Montgomery Scott
CRDL

Janney Montgomery Scott’s Cardiol Therapeutics CRDL Stock Holding History

Janney Montgomery Scott’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,200
Closed -$19K – 2880
2025
Q2 		$19K Buy
+14,200
New +$16.5K ﹤0.01% 2689

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Janney Montgomery Scott's CRDL Position: Q3 2025 in Review

Janney Montgomery Scott sold out of Cardiol Therapeutics (CRDL) in Q3 2025, closing a stake of 14,200 shares — an estimated $19K sold.

Janney Montgomery Scott first reported a position in CRDL in Q2 2025 and held it in 1 quarter. The position peaked at $19K in Q2 2025. 48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

  • Janney Montgomery Scott reported no remaining Cardiol Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 14,200 Cardiol Therapeutics shares in Q3 2025, an estimated $19K.
  • Janney Montgomery Scott first reported a position in Cardiol Therapeutics in Q2 2025 and held it in 1 quarter.
  • Janney Montgomery Scott's Cardiol Therapeutics position peaked at $19K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Janney Montgomery Scott's 13F filing for Q3 2025, filed 27 Oct 2025.